Amundi Sells 255,844 Shares of Illumina, Inc. $ILMN

Key Points

• Amundi has reduced its position in Illumina, Inc. (NASDAQ: ILMN) by 40.2%, selling 255,844 shares during the first quarter to hold a total of 380,437 shares worth approximately $29.07 million.
• Meanwhile, other institutional investors like Vanguard Group and Brown Advisory have increased their stakes in Illumina, highlighting a mixed sentiment in the market.
• Analysts have had varying outlooks on Illumina, with several raising price targets while others, including Citigroup, downgraded their ratings, resulting in a consensus target price of $123.06 and a "Hold" rating among analysts.

Amundi decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 40.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 380,437 shares of the life sciences company's stock after selling 255,844 shares during the period. Amundi owned approximately 0.24% of Illumina worth $29,073,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Fourth Dimension Wealth LLC bought a new position in shares of Illumina during the 4th quarter valued at about $40,000. Rakuten Securities Inc. boosted its position in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. bought a new position in shares of Illumina during the 1st quarter valued at about $33,000. PFS Partners LLC boosted its position in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC boosted its position in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Evercore ISI raised their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price for the company. in a report on Tuesday, August 12th. Daiwa America cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Robert W. Baird raised their target price on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Finally, Canaccord Genuity Group raised their target price on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Hold" and a consensus price target of $123.06.

Illumina Stock Down 3.3%

Shares of NASDAQ ILMN traded down $3.26 during mid-day trading on Friday, reaching $96.06. The company had a trading volume of 563,162 shares, compared to its average volume of 2,247,830. The stock has a fifty day moving average of $99.56 and a two-hundred day moving average of $88.57. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market capitalization of $14.76 billion, a price-to-earnings ratio of 12.15, a PEG ratio of 2.15 and a beta of 1.43. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.